Literature DB >> 29250223

California study of Ablation (CAABL):early utilization after index hospitalization for non-valvular atrial fibrillation.

Uma Srivatsa1, Beate Danielsen2, Ezra Amsterdam1, Yingbo Yang1, Dali Fan1, Nayereh Pezeshkian1, Richard H White2.   

Abstract

BACKGROUND: Catheter ablation (ABL) for non-valvular AF (NVAF) is recommended for symptomatic patients refractory to medical therapy and its success is related to the duration of the arrhythmia prior to intervention.Our aim was to assess the early utilization and the factors that prompted ABL in patients hospitalized for new onset NVAF.
METHODS: Using de-identified administrative discharge records for hospitalizations and emergency department (ED) visits, we determined the patients who had a first-time (since 1991) health record diagnosis of AF between2005 - 2011. We linked ambulatory surgery encounters for ABL based on ICD 9 code occurring within two years of initial hospitalization. After excluding other cardiac arrhythmias, atrio-ventricular nodal ablation or pacemaker/defibrillator placement and cardiac valve disease, bivariate comparisons were made with those who did not undergo ABL.
RESULTS: During the study period,3,440 of 424,592 patients (0.81%) hospitalized for new onset NVAF underwent ABL. Parameters significantly (p<0.001) associated with ABL compared tonon-ABL patientsincluded: principal diagnosis of AF (55% vs 25%), age 35-64 yrs (46.1% vs. 22.4%), male (58.9% vs. 48.2%), private insurance (46.6% vs. 21.1%), Caucasian (81.0% vs.71.6%), lower frequency of ED visit < 6 months before index AF hospitalization (10.7% vs. 15.9%), lower severityofillness at time of AF diagnosis (16.5% vs. 35.6%) anda lower prevalence ofmajor comorbidities (p< 0.001).
CONCLUSIONS: Ablation has low utilization for treatment of new onset NVAF within two years of diagnosis. Earlier utilization of ABL may reduce health care burden related to NVAF and requires further evaluation.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Epidemiology; Frequency

Year:  2017        PMID: 29250223      PMCID: PMC5673329          DOI: 10.4022/jafib.1599

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  52 in total

1.  Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation.

Authors:  Apoor S Gami; Dave O Hodge; Regina M Herges; Eric J Olson; Jiri Nykodym; Tomas Kara; Virend K Somers
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

Review 2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

3.  Observation of the efficacy of radiofrequency catheter ablation on patients with different forms of atrial fibrillation.

Authors:  R-C Zhao; W Han; J Han; J Yu; J Guo; J-L Fu; Z Li; R-Z Zhao
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-10       Impact factor: 3.507

4.  Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States.

Authors:  Mintu P Turakhia; Jason Shafrin; Katalin Bognar; Dana P Goldman; Philip M Mendys; Younos Abdulsattar; Daniel Wiederkehr; Jeffrey Trocio
Journal:  Am J Cardiol       Date:  2015-06-04       Impact factor: 2.778

5.  A focal source of atrial fibrillation treated by discrete radiofrequency ablation.

Authors:  P Jaïs; M Haïssaguerre; D C Shah; S Chouairi; L Gencel; M Hocini; J Clémenty
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

6.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

7.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

Authors:  S Stewart; C L Hart; D J Hole; J J McMurray
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

8.  High variation between hospitals in vena cava filter use for venous thromboembolism.

Authors:  Richard H White; Estella Marie Geraghty; Ann Brunson; Susan Murin; Ted Wun; Fred Spencer; Patrick S Romano
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

9.  The healthcare cost and utilization project: an overview.

Authors:  Claudia Steiner; Anne Elixhauser; Jenny Schnaier
Journal:  Eff Clin Pract       Date:  2002 May-Jun

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  1 in total

1.  Bariatric surgery to aLleviate OCcurrence of Atrial Fibrillation Hospitalization-BLOC-AF.

Authors:  Uma N Srivatsa; Pankaj Malhotra; Xin J Zhang; Neil Beri; Guibo Xing; Ann Brunson; Mohamed Ali; Dali Fan; Nayereh Pezeshkian; Nipavan Chiamvimonvat; Richard H White
Journal:  Heart Rhythm O2       Date:  2020-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.